Elamipretide (SS-31): The Mitochondrial Peptide That's Actually in Trials

Most peptides in the longevity and recovery scene share a frustrating profile: a neat mechanism, some mouse data, and almost no real human trials. Elamipretide — better known to biohackers by its research code SS-31 — is a genuine exception. It's been put through proper, well-designed clinical trials in serious conditions, which makes it far more interesting to look at honestly. The twist is that "actually tested" cuts both ways: real trials can also deliver real disappointments, and elamipretide's results are a genuinely mixed bag. That honesty is exactly why it's worth understanding.

What is elamipretide (SS-31)?

Elamipretide is a small peptide engineered to do something specific: travel into your cells and concentrate inside the mitochondria, the tiny "power plants" that generate most of your energy. There it binds to cardiolipin, a fat in the inner mitochondrial membrane that's essential for efficient energy production. The idea is that by stabilising that membrane, elamipretide helps damaged or ageing mitochondria make energy more effectively ³.

That matters because mitochondrial dysfunction sits at the heart of many conditions and is one of the recognised drivers of ageing, as we cover in mitochondrial health and ageing. A drug that genuinely repaired mitochondrial energy output would be a big deal — which is precisely why elamipretide has been studied so seriously, in heart failure, rare genetic diseases, muscle disorders and even eye disease.

What did the trials actually find?

Here's the honest scorecard — and it's a useful antidote to hype, because this is what real trials of a real peptide look like.

Heart failure (PROGRESS-HF). In a phase 2 trial in patients with heart failure and reduced pumping function, elamipretide did not significantly improve the main measure of heart function over four weeks compared with placebo ¹. A clear miss on the primary goal.

Barth syndrome (TAZPOWER). In this rare genetic mitochondrial disease, the main trial also missed its primary endpoint in the initial randomised phase — but during a longer open-label extension, patients showed meaningful improvements, including a roughly 25% gain in how far they could walk in six minutes ². Encouraging, but the kind of result that needs careful interpretation, since open-label extensions lack a placebo comparison.

Is it approved? Can you get it?

As of 2026, elamipretide is not approved by the FDA or other major regulators — it remains investigational, studied in ongoing trials. That's the crucial practical point: anything sold online as "SS-31" is not the clinical drug. It's an unregulated grey-market product of unknown purity and dose, with the same sourcing problems we describe across the peptide category — and self-experimenting with a mitochondria-targeting compound that careful researchers are still evaluating is exactly the scenario trials exist to prevent.

What we see at the clinic

Elamipretide appeals to people who've read about mitochondria and ageing and want to "fix the power plants" directly. We respect the science — it's one of the few peptides in this space with serious human trials, and the mitochondrial-targeting idea is elegant. But we're honest about the scoreboard: the headline trials largely missed their primary goals, the encouraging signals need confirmation, and it isn't approved. We also point out the obvious: the "SS-31" in a grey-market vial isn't the trial drug. For mitochondrial and heart health, the evidence-backed levers — exercise, sleep, not smoking, managing blood pressure and metabolic risk — remain unglamorous and far more reliable than an unproven injectable.

Common questions

Does elamipretide work? It's genuinely been tested, which is rare — but the main heart-failure trial missed its goal, and the Barth-syndrome trial missed its primary endpoint with later open-label gains ¹². The honest verdict is "promising mechanism, unproven benefit so far".

Is SS-31 the same as elamipretide? Yes — SS-31 is the research code for elamipretide. But the studied clinical drug and a grey-market "SS-31" vial are not the same product in practice.

Can I buy it legally? Not as an approved medicine — it isn't one yet. What's sold online is an unregulated research chemical.

Is it a proven anti-ageing treatment? No. It's being investigated for specific diseases; there's no approved or proven anti-ageing use, however appealing the mitochondrial theory is.

Key takeaway

Elamipretide (SS-31) is the most seriously tested peptide in this corner of the field — a clever mitochondria-targeting design that's been through real clinical trials. That's exactly why it's instructive: the trials have been honestly mixed, largely missing their primary goals while leaving some encouraging hints, and it still isn't approved. Following it is worthwhile; injecting a grey-market "SS-31" on the strength of the theory is not. Real evidence is messier than marketing — and far more trustworthy.